Corporate Profile

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cell therapy being evaluated for its potential to preserve kidney function in patients with advanced CKD and diabetes who are at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Minimum 15 minutes delayed. Source: LSEG

News Releases

Events

SEC Filings

Official notification to shareholders of matters to be brought to a vote ("Proxy")
DEF 14A
Additional proxy soliciting materials - definitive
DEFA14A
An annual report to security holders
ARS